Quick Answer
Roivant Sciences Ltd. reported Total Revenue of $29.05 million for fiscal year 2025.
Roivant Sciences Ltd. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $29.05M -11.2% |
$32.71M +3.8% |
$31.53M -43.0% |
$55.29M +132.3% |
$23.80M | — |
| Revenue (ASC 606) | $29.05M -11.2% |
$32.71M +3.8% |
$31.53M -43.0% |
$55.29M +132.3% |
$23.80M | — |
| Net Income | -$171.98M -104.0% |
$4.35B +531.0% |
-$1.01B -19.4% |
-$845.26M -4.5% |
-$809.23M | — |
| Diluted EPS | -$0.24 -104.6% |
$5.23 +468.3% |
-$1.42 -12.7% |
-$1.26 | — | — |
| Total Assets | $5.44B -24.7% |
$7.22B +202.2% |
$2.39B -7.6% |
$2.59B -0.2% |
$2.59B | — |
| Cash and Equivalents | $2.72B -58.2% |
$6.49B +287.3% |
$1.68B -18.6% |
$2.06B +0.3% |
$2.06B | — |
| Long-Term Debt | — | $430.59M +14.7% |
$375.51M +78.8% |
$210.03M +23.3% |
$170.28M | — |
| Stockholders Equity | $4.69B -21.5% |
$5.97B +415.5% |
$1.16B -30.1% |
$1.66B -7.8% |
$1.80B -13.8% |
$2.09B |
| R&D Expense | $550.41M +25.1% |
$439.91M -3.1% |
$454.06M -6.0% |
$483.04M +104.1% |
$236.63M | — |
| Operating Income | -$1.00B -122.3% |
$4.50B +595.9% |
-$906.76M +32.9% |
-$1.35B -26.2% |
-$1.07B | — |
| Shares Outstanding | 695.94M -13.7% |
806.68M +6.1% |
760.14M +9.4% |
694.98M +6.7% |
651.58M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $2.00M | -77.8% | +27.2% |
| Revenue (ASC 606) | December 31, 2025 | $2.00M | -77.8% | +27.2% |
| Net Income | December 31, 2025 | -$265.89M | -257.0% | -134.2% |
| Diluted EPS | December 31, 2025 | -$0.38 | -265.2% | -123.5% |
| Total Assets | December 31, 2025 | $5.23B | -9.8% | +3.2% |
| Cash and Equivalents | December 31, 2025 | $1.48B | -25.7% | +19.5% |
| Long-Term Debt | June 30, 2024 | $311.72M | -19.0% | -27.6% |
| Stockholders Equity | December 31, 2025 | $4.27B | -17.7% | -2.1% |
| R&D Expense | December 31, 2025 | $165.38M | +16.8% | +0.5% |
| Operating Income | December 31, 2025 | -$339.15M | -23.6% | -10.7% |
| Shares Outstanding | December 31, 2025 | 709.69M | -1.4% | +2.9% |
- Roivant Sciences Ltd. reported Total Revenue of $29.05 million for fiscal year 2025.
- Roivant Sciences Ltd. showed a decrease of -11.2% in Total Revenue compared to the prior fiscal year.
- Roivant Sciences Ltd. reported Revenue (ASC 606) of $29.05 million for fiscal year 2025.
- Roivant Sciences Ltd. showed a decrease of -11.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Roivant Sciences Ltd. reported Net Income of -$171.98 million for fiscal year 2025.
- Roivant Sciences Ltd. showed a decrease of -104.0% in Net Income compared to the prior fiscal year.
- Roivant Sciences Ltd. reported Diluted EPS of $0.24 per share (loss) for fiscal year 2025.
- Roivant Sciences Ltd. showed a decrease of -104.6% in Diluted EPS compared to the prior fiscal year.
- Roivant Sciences Ltd. reported Total Assets of $5.44 billion for fiscal year 2025.
- Roivant Sciences Ltd. showed a decrease of -24.7% in Total Assets compared to the prior fiscal year.
- Roivant Sciences Ltd. reported Cash and Equivalents of $2.72 billion for fiscal year 2025.
- Roivant Sciences Ltd. showed a decrease of -58.2% in Cash and Equivalents compared to the prior fiscal year.
- Roivant Sciences Ltd. reported Long-Term Debt of $430.59 million for fiscal year 2024.
- Roivant Sciences Ltd. showed an increase of +14.7% in Long-Term Debt compared to the prior fiscal year.
- Roivant Sciences Ltd. reported Stockholders Equity of $4.69 billion for fiscal year 2025.
- Roivant Sciences Ltd. showed a decrease of -21.5% in Stockholders Equity compared to the prior fiscal year.
- Roivant Sciences Ltd. reported R&D Expense of $550.41 million for fiscal year 2025.
- Roivant Sciences Ltd. showed an increase of +25.1% in R&D Expense compared to the prior fiscal year.
- Roivant Sciences Ltd. reported Operating Income of -$1.00 billion for fiscal year 2025.
- Roivant Sciences Ltd. showed a decrease of -122.3% in Operating Income compared to the prior fiscal year.
- Roivant Sciences Ltd. reported Shares Outstanding of 695.94 million shares for fiscal year 2025.
- Roivant Sciences Ltd. showed a decrease of -13.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: